{"id":112085,"date":"2008-05-19T07:10:36","date_gmt":"2008-05-19T11:10:36","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/asco-2008-tumor-targeted-rexin-g-demonstrates-dose-dependent-anti-tumor-activity-without-toxicity-in-metastatic-pancreatic-cancer\/"},"modified":"2008-05-19T07:10:36","modified_gmt":"2008-05-19T11:10:36","slug":"asco-2008-tumor-targeted-rexin-g-demonstrates-dose-dependent-anti-tumor-activity-without-toxicity-in-metastatic-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/asco-2008-tumor-targeted-rexin-g-demonstrates-dose-dependent-anti-tumor-activity-without-toxicity-in-metastatic-pancreatic-cancer\/","title":{"rendered":"ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer"},"content":{"rendered":"

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n

SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of an on-going Phase I\/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I\/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, beginning with 8 x 10e11 cfu to 6 x 10e12 cfu with a goal to safely reach the point where the clinical anti-tumor activity of Rexin-G would be clearly and unequivocally demonstrated.<\/p>\n

\"Caption:The results of this latest Phase I\/II study of targeted gene delivery in vivo are very encouraging-intravenous infusions of Rexin-G demonstrated significant biological activity without toxicity in patients with progressive chemo-resistant pancreatic cancer. Once the overall safety record of repeated infusions of Rexin-G was clearly demonstrated, the FDA approved across the board intra-patient dose-escalations (an adaptive design) to gain better tumor control. <\/p>\n

These higher doses of Rexin-G were associated with stabilization of disease, using both RECIST and International PET criteria, significant reductions in CA 19.9 levels, and an increase in median overall survival (greater than 6 months) which was twice that observed in the low-dose safety study. No dose-limiting toxicity was observed, even at these higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated. <\/p>\n

The importance of these progressive dose-escalation studies – which clearly establish safety before escalating to more potent tumoricidal levels – is of primary concern in the development of a new genetic medicine like Rexin-G. Moreover, the establishment of a functional dose-response relationship is also of fundamental significance, not only in terms of basic pharmacology, but in establishing the physiological mechanisms-of-action that are of major importance in determining the predictability of a new anti-cancer agent, in establishing the optimal dose regimens for a given type of cancer, and ultimately in gaining regulatory approval for Rexin-G in the United States. <\/p>\n

Taken together with the results of previous studies, the current on-going Phase I\/II study confirms the exemplary safety and therapeutic potential of Rexin-G, the first and so far only targeted gene delivery system shown to be safe and effective in the clinic. <\/p>\n

For more information about Rexin-G, on-going clinical trials in the USA and abroad, and\/or Epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erlinda M. Gordon at egordon @epeiusbiotech.com.<\/p>\n

On the Web: www.epeiusbiotech.com<\/a>.<\/p>\n

News issued by: Epeius Biotechnologies Corporation<\/p>\n

\"Epeius<\/p>\n

Original Image: https:\/\/www.send2press.com\/wire\/images\/08-0421-Epeius_72dpi.jpg<\/a><\/small><\/p>\n

# # # <\/p>\n

Original Story ID: (3986) :: 2008-05-0519-001<\/small><\/p>\n

Original Keywords: Epeius Biotechnologies Corporation, Rexin-G, pathotropic gene delivery systems, Dr. Erlinda M. Gordon, ASCO 2008, metastatic pancreatic cancer, Phase I safety study Epeius Biotechnologies Corporation <\/small><\/p>\n

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2008-05-19 07:10:36<\/p>\n","protected":false},"excerpt":{"rendered":"

SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of an on-going Phase I\/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I\/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-112085","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":467,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=112085"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112085\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=112085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=112085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=112085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}